Search for drugs:
Typing the drug name to query
TERIFLUNOMIDE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Potential to Prolong the QT Interval
- In a placebo controlled thorough QT study performed in healthy subjects, there was no evidence that teriflunomide caused QT interval prolongation of clinical significance (i.e. the upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 ms).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
2
24090
Other ADRs
98863
38282724
Odds Ratio = 0.033
Drug Property Information
ATC Code(s):
- L04AA31 - teriflunomide
- L04AA3 -
- L04AA - Selective immunosuppressants
- L04A - IMMUNOSUPPRESSANTS
- L04 - IMMUNOSUPPRESSANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:TERIFLUNOMIDE
Active Ingredient UNII:1C058IKG3B
Drugbank ID:DB08880
PubChem Compound:54684141
CTD ID: C527525
CAS Number:163451-81-8
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 14.0 mg/day L04AA31
Chemical Structure: 
SMILE Code:
C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.